The abstract is read at the publisher; the summary is JClub's.
FGFR2b, an alternatively spliced isoform of FGFR2, is a prevalent membrane cell-surface target in intrahepatic cholangiocarcinoma, present in 88.6% (institutional) and 88.2% (TCGA).
- Why it matters: iCCA has limited targeted options, and validated, tumor-prevalent cell-surface proteins are scarce, especially when gene-level analyses miss isoform-specific tumor enrichment.
- What they did: The study used isoform-resolved proteogenomics—transcriptomics, in silico translation, and cell surfaceomics—then checked specificity using TCGA and GTEx expression data and confirmed membrane staining by IHC in 20 patients.
- The result: IHC detected membrane-bound FGFR2b in 31.6% of iCCA cases, including all FGFR2 fusion patients, and high FGFR2b expression was linked to improved surgical outcomes and epithelial differentiation with reduced CD8+ T-cell infiltration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.